H.R. 1262 119th Congress
Mikaela Naylon Give Kids a Chance Act
- Health
- Sponsor: Rep. McCaul, Michael T. [R-TX-10]
- Congress.gov ↗
Latest action, Dec 2, 2025: Received in the Senate.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
313 cosponsors
Sponsored by Rep. McCaul, Michael T. [R-TX-10] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
180 D · 133 R
Referred to: House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
7 reports
7 reports
7 reports
7 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
AKIN GUMP STRAUSS HAUER & FELD
6 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
6 reports
IONIS PHARMACEUTICALS, INC.
LMH STRATEGIC SOLUTIONS
6 reports
MIGHTY THERAPEUTICS (FMRLY STEALTH BIOTHERAPEUTICS INC.)
6 reports
6 reports
PTC THERAPEUTICS, INC.
LMH STRATEGIC SOLUTIONS
6 reports
5 reports
5 reports
5 reports
All 25 of 72 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ACADIA PHARMACEUTICALS | 7 | $4.0M | Q1 2025 | Q3 2026 | yes | |
| DANA-FARBER CANCER INSTITUTE | 7 | $399K | Q1 2025 | Q3 2026 | yes | |
| HEALTHCARE INSTITUTE OF NEW JERSEY | 7 | $333K | Q1 2025 | Q3 2026 | yes | |
| IONIS PHARMACEUTICALS, INC. | 7 | $910K | Q1 2025 | Q3 2026 | yes | |
| TRAVERE THERAPEUTICS | 7 | $1.2M | Q1 2025 | Q3 2026 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | AKIN GUMP STRAUSS HAUER & FELD | 6 | $0 | Q1 2025 | Q2 2026 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) | ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) | 6 | $360K | Q1 2025 | Q2 2026 | yes |
| IONIS PHARMACEUTICALS, INC. | LMH STRATEGIC SOLUTIONS | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| MIGHTY THERAPEUTICS (FMRLY STEALTH BIOTHERAPEUTICS INC.) | 6 | $620K | Q1 2025 | Q2 2026 | yes | |
| NOVARTIS | 6 | $13.1M | Q1 2025 | Q2 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 6 | $57.5M | Q1 2025 | Q2 2026 | yes | |
| PTC THERAPEUTICS, INC. | LMH STRATEGIC SOLUTIONS | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| ALLIANCE FOR REGENERATIVE MEDICINE | 5 | $790K | Q1 2025 | Q1 2026 | yes | |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 5 | $1.3M | Q1 2025 | Q1 2026 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | 5 | $7.4M | Q1 2025 | Q1 2026 | yes | |
| BAYER CORPORATION (CONSOLIDATED REPORT) | 5 | $11.2M | Q1 2025 | Q1 2026 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 5 | $7.2M | Q1 2025 | Q1 2026 | yes | |
| BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | 5 | $2.0M | Q1 2025 | Q1 2026 | yes | |
| BRIDGEBIO PHARMA, INC. | 5 | $1.6M | Q1 2025 | Q1 2026 | yes | |
| INCYTE CORPORATION | 5 | $2.1M | Q1 2025 | Q1 2026 | yes | |
| NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) | NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES | 5 | $7.6M | Q4 2025 | Q3 2026 | yes |
| PATIENTS RISING NOW | YC CONSULTING, LLC | 5 | $200K | Q1 2025 | Q1 2026 | yes |
| PRAXIS PRECISION MEDICINES | THE KPM GROUP DC LLC | 5 | $200K | Q1 2025 | Q1 2026 | yes |
| PTC THERAPEUTICS, INC. | 5 | $1.0M | Q1 2025 | Q1 2026 | yes | |
| RARE DISEASE COMPANY COALITION | 5 | $400K | Q1 2025 | Q1 2026 | yes |